Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
IPO Year: 2016
Exchange: NASDAQ
Website: selectabio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/18/2023 | $1.00 | Outperform → Market Perform | SVB Securities |
| 6/14/2022 | $6.00 → $5.00 | Buy | Needham |
| 6/6/2022 | $7.00 | Outperform | SVB Leerink |
| 11/1/2021 | $6.00 → $7.00 | Buy | Needham |
WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022. "Blaine is a highly accomplished biopharmaceutical executive with proven financial and business development expertise," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "We are preparing for a number of key potential milestones across our pipeline
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. "I am thrilled to welcome Carsten to the Surface Oncology board," said Rob Ross, M.D., chief executive officer at Surface. "Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we ad
WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin Tan as chief financial officer. "Kevin's deep financial expertise and experience in the gene therapy and rare disease landscape makes him an ideal fit for Selecta's executive team," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "This is an exciting time for Selecta on the heels of our recent collaboration with Cyrus Biotechnology to unlock a new generation of inno
– Selecta appoints gene therapy pioneer Jude Samulski, Ph.D. as a special advisor to help guide Selecta's gene therapy programs into the clinic – – Data demonstrate that ImmTOR enhances transgene expression after both initial and repeat dosing – – Publication further validates use of ImmTOR in Selecta's gene therapy pipeline, including its lead candidate, MMA-101, for the treatment of methylmalonic acidemia (MMA) – WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB, "Selecta"))), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today a
WATERTOWN, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Nishan de Silva, M.D. to its Board of Directors. Dr. de Silva will provide strategic guidance and operational insights as Selecta continues to advance its clinical pipeline. "We are thrilled to welcome Dr. de Silva to our Board of Directors," said Carrie Cox, Chairman of Selecta's Board of Directors. "Dr. de Silva's extensive leadership experience, most relevantly in gene therapy development, manufactur
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
PRE 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
8-K/A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
S-8 - Cartesian Therapeutics, Inc. (0001453687) (Filer)
8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
8-A12G - Cartesian Therapeutics, Inc. (0001453687) (Filer)
D/A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
EFFECT - Cartesian Therapeutics, Inc. (0001453687) (Filer)
SVB Securities downgraded Selecta Biosciences from Outperform to Market Perform and set a new price target of $1.00
Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $5.00 from $6.00 previously
SVB Leerink initiated coverage of Selecta Biosciences with a rating of Outperform and set a new price target of $7.00
Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously
BTIG initiated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $10.00
William Blair upgraded Selecta Biosciences from Market Perform to Outperform
Mizuho upgraded Selecta Biosciences from Neutral to Buy
Mizuho upgraded Selecta Biosciences from Neutral to Buy and set a new price target of $8.00 from $2.50 previously
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its cli
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 - - Selecta to host conference call today at 8:30 AM ET - WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (inter
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II--In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II--75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of therapy with no infusion reactions or new safety signals--Favorable safety profile with 3.4% of patients with infusion reactions at high dose--Selecta will host a conference call and webcast today at 8:30 AM ET / 2:30 PM CET WATERTOWN, Mass. and STOCKHOLM, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB) and Sobi®, today
- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - - Continue to enroll patients in ReiMMAgine, the Phase 1/2 clinical trial of SEL-302 for the treatment of methylmalonic acidemia (MMA) - - IND enabling studies expected to commence in 2023 for interleukin-2 (IL-2) candidate to be studied in combination with ImmTOR™, as well as IgA protease candidate for the treatment of IgA Nephropathy - - As of December 31, 2022, Selecta had approximately $136.2 million in cash, cash equivalents, restricted cash and marketable securities, which is expected to provide runway into mid-2024 - - Selecta to host conference call toda
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2022 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-
– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 – – SEL-302, Selecta's wholly owned gene therapy in combination with ImmTOR for the treatment of Methylmalonic Acidemia (MMA), remains on track to begin a Phase 1 trial in Q4 2022 – – As of September 30, 2022, Selecta had approximately $148.0 million in cash, cash equivalents, restricted cash and marketable securities, which is expected to provide runway into mid-2024 – – Candidate selection for an IL-2 and IgA protease expected by year-end 2022 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --
WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that it plans to host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may ac
– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline data readout in Q1 2023 – – Sarepta extends Option and License agreement in exchange for a $2 million payment and notified Selecta of the achievement of certain pre-clinical milestones triggering a $4 million milestone payment obligation – – SEL-302, Selecta's wholly owned gene therapy in combination with ImmTOR for the treatment of Methylmalonic Acidemia (MMA) remains on track to initiate a Phase 1 trial in Q4 2022 – – As of June 30, 2022, Selecta had approximately $143.4 million in cash, ca
Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last infusion Phase 2 study of Descartes-08 in systemic lupus erythematosus expected to initiate in 1H24 Clinical pipeline expanded following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate Approximately $118M pro forma cash and cash equivalents as of D
Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC), ("the Company") a clinical-stage biotechnology company pioneering mRNA cell therap
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum AB (publ.) (Sobi). As of November 6, 2023, Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212. SEL-212, a combination of Selecta's ImmTOR immune tolerance platform
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its cli
- Phase 3 DISSOLVE I and DISSOLVE II studies both met their primary efficacy endpoints, with SEL-212-treated patients demonstrating statistically significant higher response rates compared to placebo - - SEL-212 was observed to have a favorable safety profile and was well-tolerated across both doses of ImmTOR - - BLA filing expected in 1H 2024 - WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced the presentation of positive data from the Phase 3 DISSOLVE I and D
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 - - Selecta to host conference call today at 8:30 AM ET - WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (inter
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer (CFO), Cameron Trenor, M.D., as Vice President and Head of Translational Medicine, and Anjali Kumar, Ph.D., as Vice President, Head of Business Development. In addition, Parul Doshi, M.B.A., has been promoted to Chief Data Officer in recognition of her significant contribution to the development of Cellarity and her leadership in the implementation of an efficient and scalable data infrastructure to support Cellarity's unique approach to drug creation. Cellarity is fundamentally redesignin
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II --75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of therapy with no infusion reactions or new safety signals --Favorable safety profile with 3.4% of patients with infusion reactions at high dose WATERTOWN, Mass. and STOCKHOLM, March 21, 2023 /PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ:SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled randomized cli
Selecta Biosciences Inc (NASDAQ:SELB) and Cartesian Therapeutics Inc announced a reverse merger in an all-stock deal, with Selecta shareholders owning 26.9% of the new company. In August, Selecta Biosciences provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for chronic refractory gout, which Selecta will continue to support. The combined company has been renamed Cartesian Therapeutics, with the Nasdaq ticker symbol changing to "RNAC," effective before the opening of trading tomorrow, November 14, 2023. The combined company will be led by Selecta's CEO Carsten Brunn and Cartesian co-
Concurrent with the merger, the combined company has been renamed Cartesian Therapeutics, Inc. The Company's Nasdaq ticker symbol will change to "RNAC" effective prior to the opening of trading tomorrow, November 14, 2023.
Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum AB (publ.) (Sobi). As of November 6, 2023, Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212. SEL-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in
Analysts have provided the following ratings for Selecta Biosciences (NASDAQ:SELB) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 1 0 0 Last 30D 3 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Selecta Biosciences. The company has an average price target of $3.25 with a high of $5.00 and a low of $1.00. Below is a summary of how these 4 analysts rated Selecta Biosciences over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the
Upgrades For Docebo Inc (NASDAQ:DCBO), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. For the second quarter, Docebo had an EPS of $0.14, compared to year-ago quarter EPS of $0.06. The current stock performance of Docebo shows a 52-week-high of $41.48 and a 52-week-low of $23.40. Moreover, at the end of the last trading period, the closing price was at $40.66. For American Woodmark Corp (NASDAQ:AMWD), Zelman & Assoc upgraded the previous rating of Hold to Buy. In the fourth quarter, American Woodmark showed an EPS of $2.21, compared to $1.38 from the year-ago quarter. At the moment, the stock has a 52-week-high of $78.22 and a 52-week-low of $41.20. American Wo
Mizuho analyst Uy Ear maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $4 to $3.
SVB Leerink analyst Joseph Schwartz downgrades Selecta Biosciences (NASDAQ:SELB) from Outperform to Market Perform and announces $1 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Selecta Biosciences (NASDAQ:SELB) with a Buy and maintains $5 price target.
Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $5 to $4.
Selecta Biosciences Inc (NASDAQ:SELB) provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for the treatment of chronic refractory gout, which Selecta will continue to support. To preserve capital, the company plans to suspend further investment in its pipeline assets, including ImmTOR-IL, and instead focus on maximizing the value of its pipeline through potential licensing and corporate development activities. These initiatives are expected to extend its cash runway into 2027. "At Selecta, we remain committed to SEL-212, a potentially unique and differentiated once-monthly uricase-based
SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13D - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13D - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13D/A - SELECTA BIOSCIENCES INC (0001453687) (Subject)
SC 13G - SELECTA BIOSCIENCES INC (0001453687) (Subject)
SC 13G/A - SELECTA BIOSCIENCES INC (0001453687) (Subject)
SC 13G - SELECTA BIOSCIENCES INC (0001453687) (Subject)